Farydak
Active Ingredient(s): PanobinostatFDA Approved: * February 23, 2015
Pharm Company: * NOVARTIS PHARMS CORP
Category: Cancer
Panobinostat, sold under the brand name Farydak, is a medication used for the treatment of various cancers. It is a hydroxamic acid[2] and acts as a non-selective histone deacetylase inhibitor (pan-HDAC inhibitor).[3] On 23 February 2015 it received FDA accelerated approval for use in patients with multiple myeloma,[4][5] and on 28 August 2015 it was approved by the European Medicines Agency for the same use.[6] ... [wikipedia]
* May have multiple approval dates, manufacturers, or labelers.